

5

Docket No. G-078US05DIV
Serial No. 10/643,836In the Claims

1 (currently amended). An isolated polypeptide comprising an amino acid sequence at least ~~90%~~, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 297.

2 (original). The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 297.

3 (original). The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence encoded by a human cDNA of Clone 181-3-3-0-C9-CS in ATCC accession number PTA-1218.

4 (original). The polypeptide of claim 1, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 297.

5 (original). The polypeptide of claim 1, where said polypeptide plays a role in vesicle trafficking.

6 (original). The polypeptide of claim 2, wherein said polypeptide plays a role in vesicle trafficking.

7 (original). The polypeptide of claim 3, wherein said polypeptide plays a role in vesicle trafficking.

8 (original). The polypeptide of claim 4, wherein said polypeptide plays a role in vesicle trafficking.

J:\GEN\078.US05.DIVAmd-Resp\Amd.doc\DNB\gyl

6

Docket No. G-078US05DIV
Serial No. 10/643,836

9 (currently amended). A composition comprising an isolated polypeptide comprising an amino acid sequence at least ~~90%~~, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 297 and a pharmaceutically acceptable carrier.

10 (original). The composition of claim 9, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 297.

11 (original). The composition of claim 9, wherein said polypeptide comprises an amino acid sequence encoded by a human cDNA of Clone 181-3-3-0-C9-CS in ATCC accession number PTA-1218.

12 (original). The composition of claim 9, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 297.

13 (original). The composition of claim 9, where said polypeptide plays a role in vesicle trafficking.

14 (original). The composition of claim 10, wherein said polypeptide plays a role in vesicle trafficking.

15 (original). The composition of claim 11, wherein said polypeptide plays a role in vesicle trafficking.

16 (original). The composition of claim 12, wherein said polypeptide plays a role in vesicle trafficking.

17 (new). The polypeptide according to claim 5, wherein said polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 297.

J:\GEN078.US05.DIV\Amd-Resp\Amd.doc\DNB\gyl

7

Docket No. G-078US05DIV
Serial No. 10/643,836

18 (new). The polypeptide according to claim 5, wherein said polypeptide comprises an amino acid sequence at least 96% identical to SEQ ID NO: 297.

19 (new). The polypeptide according to claim 5, wherein said polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 297.

20 (new). The polypeptide according to claim 5, wherein said polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 297.

21 (new). The polypeptide according to claim 5, wherein said polypeptide comprises an amino acid sequence at least 99% identical to SEQ ID NO: 297.

22 (new). The composition according to claim 13, wherein said polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 297.

23 (new). The composition according to claim 13, wherein said polypeptide comprises an amino acid sequence at least 96% identical to SEQ ID NO: 297.

24 (new). The composition according to claim 13, wherein said polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 297.

25 (new). The composition according to claim 13, wherein said polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 297.

26 (new). The composition according to claim 13, wherein said polypeptide comprises an amino acid sequence at least 99% identical to SEQ ID NO: 297.

J:\GEN078.US05.DIV\Amd-Resp\Amd.doc\DNB\gyI